Baudax Bio, Inc. BXRX
We take great care to ensure that the data presented and summarized in this overview for Baudax Bio, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in BXRX
Top Purchases
Top Sells
About BXRX
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
Insider Transactions at BXRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 15
2022
|
Geraldine Henwood President and CEO |
BUY
Open market or private purchase
|
Direct |
1,200
+33.09%
|
$2,400
$2.55 P/Share
|
|
Jun 15
2022
|
Wayne Weisman Director |
BUY
Grant, award, or other acquisition
|
Direct |
39,473
+47.92%
|
-
|
|
Jun 15
2022
|
Geraldine Henwood President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
39,473
+44.57%
|
-
|
|
Jun 15
2022
|
Jillian Dilmore Corporate Controller/Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
15,467
+49.57%
|
-
|
|
Jun 15
2022
|
Andrew T Drechsler Director |
BUY
Grant, award, or other acquisition
|
Direct |
39,473
+48.65%
|
-
|
|
Jun 15
2022
|
Winston J Churchill Director |
BUY
Grant, award, or other acquisition
|
Direct |
39,473
+45.74%
|
-
|
|
Jun 15
2022
|
Arnold M Baskies Director |
BUY
Grant, award, or other acquisition
|
Direct |
39,473
+48.48%
|
-
|
|
Jun 15
2022
|
William Ashton Director |
BUY
Grant, award, or other acquisition
|
Direct |
39,473
+48.13%
|
-
|
|
Dec 15
2021
|
Geraldine Henwood President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
18,636
-5.24%
|
$0
$0.31 P/Share
|
|
Dec 05
2021
|
Geraldine Henwood President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
9,155
-2.51%
|
$0
$0.35 P/Share
|
|
Sep 22
2021
|
Geraldine Henwood President and CEO |
BUY
Open market or private purchase
|
Direct |
8,200
+2.2%
|
$0
$0.59 P/Share
|
|
Aug 31
2021
|
Winston J Churchill Director |
BUY
Open market or private purchase
|
Direct |
100,000
+28.0%
|
$0
$0.63 P/Share
|
|
Aug 20
2021
|
Richard S Casten Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
50,000
+20.0%
|
$0
$0.51 P/Share
|
|
Jun 07
2021
|
Winston J Churchill Director |
BUY
Open market or private purchase
|
Direct |
25,000
+7.62%
|
$0
$0.78 P/Share
|
|
May 14
2021
|
Richard S Casten Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
25,000
+14.29%
|
$0
$0.79 P/Share
|
|
May 11
2021
|
Arnold M Baskies Director |
BUY
Open market or private purchase
|
Direct |
10,000
+10.37%
|
$0
$0.82 P/Share
|
|
May 07
2021
|
Geraldine Henwood President and CEO |
BUY
Open market or private purchase
|
Direct |
6,000
+1.66%
|
$0
$0.83 P/Share
|
|
Apr 07
2021
|
Alfred Altomari Director |
BUY
Grant, award, or other acquisition
|
Direct |
56,452
+32.4%
|
-
|
|
Apr 07
2021
|
William Ashton Director |
BUY
Grant, award, or other acquisition
|
Direct |
56,452
+34.5%
|
-
|
|
Apr 07
2021
|
Winston J Churchill Director |
BUY
Grant, award, or other acquisition
|
Direct |
56,452
+29.93%
|
-
|